Bristol/Agios AML Drug Idhifa Fails In Phase III

IDHENTIFY Studied The IDH2 Inhibitor In Its Approved Indication

 
• By Mandy Jackson
  
microscope
Idhifa missed the overall survival endpoint in Phase III
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D